Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04598542 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
A Phase 1 study, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04598542 is a Phase 1 study that has completed, run by Biosplice Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT04598542, a Phase 1 study, has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will be an open-label, parallel-arm study to determine if a prior intra-articular (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone acetonide (TA) into the same knee, and to determine if a prior IA injection of TA affects the safety or tolerability of a subsequent IA injection of LOR into the same knee.
Interventions
- DRUG Lorecivivint (LOR)
- DRUG Triamcinolone acetonide (TA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04598542
The ClinicalTrials.gov registry entry for NCT04598542 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lorecivivint (LOR) is the first listed.
NCT04598542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04598542 about?
NCT04598542 is a clinical study titled "Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers". This study will be an open-label, parallel-arm study to determine if a prior intra-articular (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone acetonide (TA) into the same knee, and to ...
What is the current status of trial NCT04598542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-10-13. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT04598542?
The interventions under investigation include: Lorecivivint (LOR) (DRUG), Triamcinolone acetonide (TA) (DRUG).
Who is sponsoring clinical trial NCT04598542?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.